Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)
China · Delayed Price · Currency is CNY 22.19
-0.43 (-1.90%)
May 12, 2026, 3:00 PM CST
Aurisco Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,676 | 1,689 | 1,472 | 1,254 | 1,001 | 800.46 |
Other Revenue | 8.73 | 8.73 | 3.67 | 8.59 | 7.23 | 2.9 |
| 1,685 | 1,697 | 1,476 | 1,263 | 1,008 | 803.36 | |
Revenue Growth (YoY) | 9.25% | 15.02% | 16.89% | 25.24% | 25.48% | 11.36% |
Cost of Revenue | 720.88 | 697.29 | 631.38 | 564.22 | 495.51 | 408.64 |
Gross Profit | 963.86 | 1,000 | 844.36 | 698.32 | 512.57 | 394.72 |
Selling, General & Admin | 306.78 | 297.25 | 300.7 | 270.49 | 175.27 | 136 |
Research & Development | 159.01 | 153.39 | 146.34 | 136.89 | 117.26 | 69.35 |
Other Operating Expenses | 11.4 | 9.32 | 7.38 | 7.93 | 7.63 | 6.7 |
Operating Expenses | 484.84 | 467.62 | 457.96 | 419.48 | 304.36 | 211.96 |
Operating Income | 479.02 | 532.56 | 386.4 | 278.83 | 208.21 | 182.76 |
Interest Expense | -34.71 | -34.71 | -15.78 | -2.74 | -1.01 | -0.64 |
Interest & Investment Income | 21.8 | 19.91 | 18.31 | 48.25 | 4.41 | 8.94 |
Currency Exchange Gain (Loss) | -9.83 | -9.83 | 18.24 | 3.58 | 24.86 | -7.44 |
Other Non Operating Income (Expenses) | -11.5 | 2.25 | -0.89 | -1.62 | -0.63 | 0.79 |
EBT Excluding Unusual Items | 444.78 | 510.18 | 406.28 | 326.31 | 235.84 | 184.41 |
Gain (Loss) on Sale of Investments | 5.44 | 4.44 | 2.25 | - | -1.19 | - |
Gain (Loss) on Sale of Assets | -0.54 | -0.55 | -0.41 | -1.53 | -1.5 | -0.4 |
Asset Writedown | -0.23 | -0.23 | -0.17 | - | - | - |
Other Unusual Items | 4.45 | 4.45 | -1.04 | 4.3 | 7.59 | 8 |
Pretax Income | 453.9 | 518.3 | 407.39 | 329.08 | 240.75 | 192.01 |
Income Tax Expense | 60.18 | 69.09 | 52.6 | 40.01 | 32.47 | 23.73 |
Earnings From Continuing Operations | 393.72 | 449.21 | 354.79 | 289.07 | 208.28 | 168.28 |
Minority Interest in Earnings | - | - | - | 0.35 | 2.69 | 0.43 |
Net Income | 393.72 | 449.21 | 354.79 | 289.42 | 210.96 | 168.71 |
Net Income to Common | 393.72 | 449.21 | 354.79 | 289.42 | 210.96 | 168.71 |
Net Income Growth | 0.43% | 26.61% | 22.59% | 37.19% | 25.04% | 7.31% |
Shares Outstanding (Basic) | 401 | 401 | 399 | 408 | 406 | 402 |
Shares Outstanding (Diluted) | 409 | 408 | 399 | 408 | 406 | 402 |
Shares Change (YoY) | 3.37% | 2.44% | -2.21% | 0.48% | 1.00% | 7.31% |
EPS (Basic) | 0.98 | 1.12 | 0.89 | 0.71 | 0.52 | 0.42 |
EPS (Diluted) | 0.96 | 1.10 | 0.89 | 0.71 | 0.52 | 0.42 |
EPS Growth | -2.84% | 23.60% | 25.35% | 36.54% | 23.81% | - |
Free Cash Flow | 132.29 | 71.42 | -207.87 | 80.13 | -49.82 | -49.04 |
Free Cash Flow Per Share | 0.32 | 0.17 | -0.52 | 0.20 | -0.12 | -0.12 |
Dividend Per Share | 0.340 | 0.340 | 0.290 | 0.220 | 0.160 | 0.130 |
Dividend Growth | 17.24% | 17.24% | 31.82% | 37.50% | 23.08% | 8.33% |
Gross Margin | 57.21% | 58.92% | 57.22% | 55.31% | 50.85% | 49.13% |
Operating Margin | 28.43% | 31.37% | 26.18% | 22.09% | 20.65% | 22.75% |
Profit Margin | 23.37% | 26.46% | 24.04% | 22.92% | 20.93% | 21.00% |
Free Cash Flow Margin | 7.85% | 4.21% | -14.09% | 6.35% | -4.94% | -6.11% |
EBITDA | 607.49 | 651.87 | 469.05 | 352.98 | 273.15 | 234.22 |
EBITDA Margin | 36.06% | 38.40% | 31.78% | 27.96% | 27.10% | 29.15% |
D&A For EBITDA | 128.47 | 119.3 | 82.65 | 74.15 | 64.94 | 51.47 |
EBIT | 479.02 | 532.56 | 386.4 | 278.83 | 208.21 | 182.76 |
EBIT Margin | 28.43% | 31.37% | 26.18% | 22.09% | 20.65% | 22.75% |
Effective Tax Rate | 13.26% | 13.33% | 12.91% | 12.16% | 13.49% | 12.36% |
Revenue as Reported | 1,697 | 1,697 | 1,476 | 1,263 | 1,008 | 803.36 |
Advertising Expenses | - | 38.53 | 56.72 | 33.73 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.